Price
No data yet.
Social Signal Score
Revenue
$802.00M+24.34%Company Profile
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Beta
- 0.58
Financials
IMS has only 10 quarterly periods on file — the charts below show the full history available.
Revenue
$802.00M+24.3%Net Income
$24.00MEBITDA
$169.00M+0.0%Free Cash Flow
$92.00MEPS (diluted)
$0.07Shares Outstanding (diluted)
335.60M+19.9%Operating Expenses
$168.00MCash & Debt
$368.00MReturn of Capital
$26.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2015 | $2.92B | $417.00M | $1.26 |
| 2014 | $2.64B | $-189.00M | $-0.59 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.85
- Implied price
- $37.02
- Return from $31.34
- 3.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $18.41 — -41.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -2.0% | -12.6% | -9.2% | -6.2% | -3.5% | -1.1% |
| 3.0% | -8.2% | -4.6% | -1.4% | 1.4% | 3.9% |
| 8.0% | -3.7% | 0.1% | 3.4% | 6.3% | 9.0% |
| 13.0% | 0.7% | 4.7% | 8.2% | 11.2% | 14.0% |
| 18.0% | 5.2% | 9.3% | 13.0% | 16.2% | 19.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·5h ago·Neutral
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide's Dual Mechanism of Action
View source ↗ - Newsglobenewswire.com·22d ago·Neutral
…atory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the immunomodulatory effects of cemsidomide in combination with …
View source ↗
Insider trading
Open-market buys and sells by IMS officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IMS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.